Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association Between Patient Safety Culture and Missed Nursing Care in Healthcare Settings: A Systematic Review and Meta-Analysis.
J Adv Nurs
January 2025
College of Nursing, Sultan Qaboos University, Seeb, Oman.
Aim: To appraise and synthesise existing research on the relationship between patient safety culture and missed nursing care.
Design: Systematic review and meta-analysis.
Methods: Peer-reviewed articles published from 2010 onwards were searched from five databases (CINAHL, ProQuest, PubMed, ScienceDirect and Web of Science).
Principal investigator gender and clinical trial success: analysis of over 3000 obstetrics and gynecology trials.
AJOG Glob Rep
February 2025
Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL (Steinberg, Young, Strom, Andebrhan, Perry, Barry, Holder, Roque, and Yee).
Background: In obstetrics and gynecology (OBGYN) research, gender disparities permeate through leadership, funding, promotion, mentorship, publishing, compensation, and publicity. Few studies have investigated OBGYN clinical trial leadership as it relates to investigator gender. Thus, we undertook an investigation of principal investigator (PI) gender and clinical trial success.
View Article and Find Full Text PDFInitial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Front Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFA phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Access improvement in healthcare: a 12-step framework for operational practice.
Front Health Serv
January 2025
Department of Radiation Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, United States.
Background: Access improvement is a fundamental component of value-based healthcare as it inherently promotes quality by eliminating chokepoints, redundancies, and inefficiencies which could hinder the provisioning of timely care. The purpose of this review is to present a 12-step framework which offers healthcare organizations a practical, thematic-based foundation for thinking about access improvement.
Methods: This study was designed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!